

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



Proteins

Screening Libraries

Product Data Sheet

SIBA

Cat. No.: HY-18684 CAS No.: 35899-54-8 Molecular Formula: $C_{14}H_{21}N_5O_3S$ Molecular Weight: 339.41

Target: HSV; Nucleoside Antimetabolite/Analog; Parasite

Pathway: Anti-infection; Cell Cycle/DNA Damage

In solvent

Powder -20°C Storage: 3 years

> 2 years -80°C 2 years

-20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (294.63 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.9463 mL	14.7314 mL	29.4629 mL
	5 mM	0.5893 mL	2.9463 mL	5.8926 mL
	10 mM	0.2946 mL	1.4731 mL	2.9463 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

SIBA (5'-Isobutylthioadenosine) is a transmethylation inhibitor (SAH (HY-19528) analogue), with potent anti-proliferative activity. SIBA reversibly inhibits the production of HSV-1 by blocking methylation, specifically by blocking the 5' end-capping of viral mRNA. SIBA also inhibits the growth of tumour cells in vitro and metastatic spread in vivo. SIBA can be used in cancer, HSV-1 infection and anti-malaria studies [1][2][3].

HSV-1 IC₅₀ & Target Plasmodium

Page 1 of 3

In Vitro

SIBA (0.5 mM; 24-96 h) shows strong anti-proliferative activity against 3LL and RMS-J1 tumour cells $^{[1]}$.

SIBA (1 mM; 12, 24 h) reversibly inhibits HSV production in HEp2 cells (infected by HSV-1)^[2].

SIBA inhibits protein synthesis by 98% after 10 h infection of HEp2 cells (infected by HSV-1)^[2].

12,24 h

SIBA (1 mM; 8.5 h) inhibits protein synthesis and RNA methylation in HEp2 cells (infected by HSV-1)^[2].

SIBA (0.5, 1.0 mM; 24, 48 h) inhibits the conversion of putrescine into spermidine and/or spermine and that this inhibition is a reversible one (interferes with polyamine biosynthesis, probably by blocking aminopropyltransferase)^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	3 LL and RMS-J1 cells	
Concentration:	0.5 mM	
Incubation Time:	24-96 h	
Result:	Inhibited 3LL and RMS-J1 tumor cell growth potently by 96% and 88%, respectively.	
Cell Viability Assay ^[2]		
Cell Line:	HEp2 cells (infected by HSV-1)	
Concentration:	1 mM	

Cell Viability Assay^[2]

Incubation Time:

Result:

Cell Line:	HEp2 cells (infected by HSV-1)
Concentration:	1 mM
Incubation Time:	8.5 h
Result:	Reduced protein synthesis by 41.3% in normal medium and by 63.5% in medium poor in methionine. Inhibited RNA methylation by 65.4%.

Decreased virus production by 88.4 and 98.2% when at 12 and 24 h, respectively.

Cell Viability Assay^[3]

Cell Line:	chick embryo fibroblasts
Concentration:	0.5, 1.0 mM
Incubation Time:	24, 48 h
Result:	Inhibited the uptake of the radioactive diamine and that the inhibition was dose-dependent.

In Vivo

SIBA (150 mg/kg; i.p.; twice weekly for 3 weeks) inhibits tumor growth in vivo $^{[1]}$. SIBA (15 mg/kg; i.p.; thrice weekly for 4 weeks) inhibits metastatic spread of RMS-J1 cells in vivo $^{[1]}$. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 female mice (4-8 weeks old) $^{[1]}$.	
Dosage:	150 mg/kg	
Administration:	Intraperitoneal injection; twice weekly for 3 weeks.	
Result:	Significantly reduced the median number of lung metastases.	
Animal Model:	Adult syngeneic Wistar AG rats (8-week-old; subcutaneously grafted with RMS-J1 cells) $^{[1]}$.	
Dosage:	15 mg/kg	
Administration:	Intraperitoneal injection; thrice weekly for 4 weeks.	
Result:	Inhibited in vivo metastatic spread of RMS-J1 cells, and showed median numbers of lung metastatic nodules was 26.	

REFERENCES

- [1]. Lawrence F, et al. Effect of 5'-deoxy-5'-isobutylthioadenosine on putrescine uptake and polyamine biosynthesis by chick embryo fibroblasts. Biochem J. 1982 Jun 15;204(3):853-9.
- [2]. F Breillout, et al. Association of SIBA treatment and a Met-depleted diet inhibits in vitro growth and in vivo metastatic spread of experimental tumor cell lines. Clin Exp Metastasis. Jan-Feb 1988;6(1):3-16.
- [3]. B Jacquemont, et al. Inhibition of viral RNA methylation in herpes simplex virus type 1-infected cells by 5' S-isobutyl-adenosine. J Virol. 1977 Apr;22(1):160-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA